Karim Fizazi, MD, PhDEnriched profile
General Director (Directeur Général) of Centre Oscar Lambret; Professor of Oncology, Université Paris-Saclay; Medical Oncologist · Université de Lille
Overview
Updated 14 Jul 2026
Karim Fizazi is General Director (Directeur Général) of Centre Oscar Lambret. The public record shows 1,575 publications with 84,733 citations (h-index 125), centered on Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Prostate Cancer Diagnosis and Treatment. It also documents an investigator role on 23 registered clinical trials.
- Most recent indexed publication: 2026 · American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
- Top research focus: Prostate Cancer Treatment and Research
- 23 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 22 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 535.
Clinical & industrytrials, payments and federal funding
Not shown. No U.S. clinical registration on file.
Federally funded research awards.
Public positionssourced statements on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centreoscarlambret.fr ↗
This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 23 registered studies on ClinicalTrials.gov. The most recent:
- Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
Sponsor: UNICANCER
InvestigatorPhase 3RecruitingNCT06625970 - Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
Sponsor: UNICANCER
InvestigatorPhase 3RecruitingNCT06496581 - Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
InvestigatorPhase 3RecruitingNCT05874063
Industry payments
Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Optimizing Care for Patients With Metastatic Castration-Resistant Prostate Cancer.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
2026 - Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.
Journal of clinical oncology
2026 - Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).
Future oncology (London, England)
2025
Most-cited worksby citation count (OpenAlex)
- 01Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy4,583 citations2012
- 02Abiraterone and Increased Survival in Metastatic Prostate Cancer4,400 citations2011
- 03Enzalutamide in Metastatic Prostate Cancer before Chemotherapy3,036 citations2014
- 04Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy2,796 citations2012
- 05Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer2,618 citations2021
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
Centre Oscar Lambret, 3 rue Frédéric Combemale, 59000 Lille, France
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →theranostictrials.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centreoscarlambret.fr ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gustaveroussy.fr ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bulletins-officiels.social.gouv.fr ↗
- Chair
French Genitourinary Tumour Group (GETUG)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centreoscarlambret.fr ↗ - Head
genitourinary oncology group, Institut Gustave Roussy
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gustaveroussy.fr ↗
Awards & honorshonors on the public record
- Hubertus Wald Prize in Oncology 2025 (University Hospital Hamburg-Eppendorf)
for research advancing prostate/testicular tumor therapies
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗ - ESMO Award 2022
for pioneering research in genitourinary (prostate, ureter, bladder, testis) cancers
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →drozdogan.com ↗
Secondary affiliationsappointments beyond the home institution
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centreoscarlambret.fr ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centreoscarlambret.fr ↗
- Institut Gustave Roussy
Villejuif, Medical Oncologist; directed the Department of Cancer Medicine 2005-2018; head of genitourinary oncology group
2018verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gustaveroussy.fr ↗
Media & interviewspress, podcasts and appearances
- UroToday video lecture series
multiple interviews including PEACE-2 trial results (ASCO GU 2026) and treatment-decision discussions in castration-resistant prostate cancer
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urotoday.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- The ASCO Post video interview
"Karim Fizazi on Prostate Cancer Abiraterone Acetate, Prednisone, and Radiotherapy in Metastatic Disease"
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- LinkedIn
fr.linkedin.com/in/karim-fizazi-93572a3b9
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fr.linkedin.com ↗
Mentions by otherswhere others cite or feature them
- Facebook
facebook.com/CentreOscarLambret/posts/1476379280581282
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Other
centreoscarlambret.fr/dr-karim-fizazi
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centreoscarlambret.fr ↗ - X / Twitter
N/A
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →source ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
- 1,431
- publications
- 164
- h-index
- 8
- trials
Toni Choueiri, MD
Brigham and Women's Hospital
- 2,494
- publications
- 152
- h-index
- 12
- trials
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
- 1,588
- publications
- 150
- h-index
- 18
- trials
Fred Saad, MD
Centre Hospitalier de l’Université de Montréal
- 1,915
- publications
- 128
- h-index
- 7
- trials